New Drug Approvals Archive - January 2009
AllerNaze (triamcinolone acetonide) Nasal Spray - formerly AllerNase
Date of Approval: January 7, 2009
AllerNaze, formerly Tri-Nasal (triamcinolone acetonide, USP) is a reformulated aqueous intranasal steroid nasal spray indicated for the once daily treatment of nasal symptoms associated with both seasonal and perennial allergic rhinitis in adults and children twelve years of age and older.
Zingo (lidocaine hydrochloride monohydrate)
Patient Population Altered: January 8, 2009
Date of Approval: January 14, 2009
Savella (milnacipran) is a selective serotonin and norepinephrine reuptake inhibitor indicated for the management of fibromyalgia.
RiaSTAP (Fibrinogen Concentrate (Human))
Date of Approval: January 16, 2009
RiaSTAP (Fibrinogen Concentrate (Human)) is lyophilized fibrinogen for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Gelnique (oxybutynin hydrochloride) Topical Gel - formerly OTG
Date of Approval: January 27, 2009
Gelnique (oxybutynin chloride) Gel is a transdermal antispasmodic which is applied to the skin once daily for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.
Kapidex (dexlansoprazole) Delayed Release Capsules - formerly TAK-390MR
Date of Approval: January 30, 2009
Kapidex (dexlansoprazole) is a proton pump inhibitor with a novel delivery system approved for the treatment of erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).
Vectical (calcitriol) Ointment
Date of Approval: January 23, 2009
Vectical Ointment is a Vitamin D analog indicated for the topical treatment of mild to moderate plaque psoriasis in adults 18 years and older.